Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated

PURPOSE Meningiomas are the most frequent primary intracranial tumors. Patient outcome varies widely from benign to highly aggressive, ultimately fatal courses. Reliable identification of risk of progression for individual patients is of pivotal importance. However, only biomarkers for highly aggressive tumors are established (CDKN2A/B and TERT), whereas no molecularly based stratification exists for the broad spectrum of patients with low- and intermediate-risk meningioma. METHODS DNA methylation data and copy-number information were generated for 3,031 meningiomas (2,868 patients), and mutation data for 858 samples. DNA methylation subgroups, copy-number variations (CNVs), mutations, and WHO grading were analyzed. Prediction power for outcome was assessed in a retrospective cohort of 514 patients, validated on a retrospective cohort of 184, and on a prospective cohort of 287 multicenter cases. RESULTS Both CNV- and methylation family–based subgrouping independently resulted in increased prediction accuracy of risk of recurrence compared with the WHO classification (c-indexes WHO 2016, CNV, and methylation family 0.699, 0.706, and 0.721, respectively). Merging all risk stratification approaches into an integrated molecular-morphologic score resulted in further substantial increase in accuracy (c-index 0.744). This integrated score consistently provided superior accuracy in all three cohorts, significantly outperforming WHO grading (c-index difference P = .005). Besides the overall stratification advantage, the integrated score separates more precisely for risk of progression at the diagnostically challenging interface of WHO grade 1 and grade 2 tumors (hazard ratio 4.34 [2.48-7.57] and 3.34 [1.28-8.72] retrospective and prospective validation cohorts, respectively). CONCLUSION Merging these layers of histologic and molecular data into an integrated, three-tiered score significantly improves the precision in meningioma stratification. Implementation into diagnostic routine informs clinical decision making for patients with meningioma on the basis of robust outcome prediction.

[1]  John S. Phillips.  Royalties , 2021, Tax Treaty Networks 1991.

[2]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[3]  J. Barnholtz-Sloan,et al.  Epidemiology of Brainstem High-Grade Gliomas in Children and Adolescents in the United States, 2000-2017. , 2020, Neuro-oncology.

[4]  Lisa C. Wallace,et al.  The Meningioma Enhancer Landscape Delineates Novel Subgroups and Drives Druggable Dependencies. , 2020, Cancer discovery.

[5]  David T. W. Jones,et al.  CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas , 2020, Acta Neuropathologica.

[6]  K. Aldape,et al.  Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes , 2020, Nature Medicine.

[7]  G. Reifenberger,et al.  cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas , 2020, Acta Neuropathologica.

[8]  Pieter Wesseling,et al.  cIMPACT‐NOW: a practical summary of diagnostic points from Round 1 updates , 2019, Brain pathology.

[9]  Raymond Y Huang,et al.  DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. , 2019, Neuro-oncology.

[10]  David T. W. Jones,et al.  Mutational patterns and regulatory networks in epigenetic subgroups of meningioma , 2019, Acta Neuropathologica.

[11]  G. Reifenberger,et al.  cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” , 2018, Acta Neuropathologica.

[12]  Julie M. Batten,et al.  DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome , 2018, Acta Neuropathologica.

[13]  Y. Marie,et al.  Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing , 2017, Acta Neuropathologica.

[14]  Martin Sill,et al.  DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. , 2017, The Lancet. Oncology.

[15]  Mark W. Youngblood,et al.  Integrated genomic analyses of de novo pathways underlying atypical meningiomas , 2017, Nature Communications.

[16]  David T. W. Jones,et al.  Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma , 2017, Acta Neuropathologica.

[17]  M. Weller,et al.  EANO guidelines for the diagnosis and treatment of meningiomas. , 2016, The Lancet. Oncology.

[18]  Mark W. Youngblood,et al.  Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas , 2016, Nature Genetics.

[19]  K. Aldape,et al.  TERT Promoter Mutations and Risk of Recurrence in Meningioma. , 2016, Journal of the National Cancer Institute.

[20]  A. Vortmeyer,et al.  Integrated genomic characterization of IDH1-mutant glioma malignant progression , 2015, Nature Genetics.

[21]  Alberto Orfao,et al.  Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. , 2014, Neuro-oncology.

[22]  J. Rahnenführer,et al.  Molecular Biological Determinations of Meningioma Progression and Recurrence , 2014, PloS one.

[23]  Murim Choi,et al.  Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO , 2013, Science.

[24]  Thomas C. Chen,et al.  DNA Methylation in the Malignant Transformation of Meningiomas , 2013, PloS one.

[25]  Robert T. Jones,et al.  Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations , 2013, Nature Genetics.

[26]  Thomas Lengauer,et al.  Application of oncogenetic trees mixtures as a biostatistical model of the clonal cytogenetic evolution of meningiomas , 2007, International journal of cancer.

[27]  Arie Perry,et al.  Histological classification and molecular genetics of meningiomas , 2006, The Lancet Neurology.

[28]  A. Órfão,et al.  New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.